In Brief: A New Donanemab (Kisunla) Dosing Regimen for Alzheimer's Disease

The FDA has approved a new titration regimen for donanemab (Kisunla – Lilly),1 an IV amyloid beta-directed monoclonal antibody indicated for treatment of Alzheimer's disease. The new regimen is intended to reduce the risk of serious amyloid-related imaging abnormalities (ARIA) associated with use of the drug.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-08-18
DOI: https://doi.org/10.58347/tml.2025.1735d
Primary Topic: Cholinesterase and Neurodegenerative Diseases
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

In Brief: A New Donanemab (Kisunla) Dosing Regimen for Alzheimer's Disease

Aug 18, 2025

The medical letter on drugs and therapeutics/The medical letter

Cholinesterase and Neurodegenerative Diseases

article

In Brief: A New Donanemab (Kisunla) Dosing Regimen for Alzheimer's Disease

August 18, 2025article en

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1735)

Openalex Percentile: Top 77%

Cholinesterase and Neurodegenerative Diseases

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In Brief: A New Donanemab (Kisunla) Dosing Regimen for Alzheimer's Disease · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS